Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.

David Boutolleau,Ana Canestri,Sonia Burrel,Marc Wirden,Sophie Seang,Cyril Clavel-Osorio,Anne-Geneviève Marcelin,Christine Katlama,Henri Agut

Journal of Clinical Virology（2012）

引用 9|浏览9

暂无评分

摘要

Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication. We describe herein the emergence of CMV resistance to FOS in a 54-year-old man receiving FOS salvage therapy because of multidrug-resistant HIV-1 infection. Oral valganciclovir (VGCV) treatment allowed subsequently the improvement of FOS-resistant CMV infection.

查看译文

关键词

HIV,Foscarnet salvage therapy,Cytomegalovirus resistance,Risk factors,Viral monitoring

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要